Healio Modeling Endocrinology Practices for Mitigating Cardiovascular-Renal-Metabolic Risks With GLP-1-Based Therapies in T2D
Type 2 diabetes (T2D) rarely travels alone. Most patients carry overlapping cardiovascular, renal, and metabolic (CKM) risk, and this convergence is now central to how T2D should be managed, not a comorbidity footnote. Despite clear guideline recommendations, GLP-1 RAs and dual GIP/GLP-1 RAs with proven cardiovascular and renal benefit remain underused among patients who stand to gain the most. Patient complexity, an expanding evidence base for outcomes, and persistent clinical inertia all contribute to this gap.
Endocrinologists, endocrinology NPs and PAs, and the broader care team are positioned to close it. This training program, modeled on the CDC Training of Trainers approach, equips endocrinology-led teams to build CKM risk into everyday T2D decision-making: selecting and sequencing GLP-1-based therapies according to a patient’s cardiovascular, renal, and metabolic profile, not glycemic control alone. The content also addresses related benefits emerging in this drug class, including MASH and OSA, within the broader CKM framework.Designed to update clinicians on data presented at the American Society of Retina Specialists 43rd Annual Meeting held in Long Beach, CA, from July 30 to August 2, 2025
Expert thought leaders provide insights to help clinicians apply these findings to their management of patients with nAMD, DME, and RVO when using newer therapies that support longer treatment intervals.
Cost: Free
View Offer chevron_rightKey Features
Modeling Endocrinology Practices for Mitigating Cardiovascular-Renal-Metabolic Risks With GLP-1-Based Therapies in T2D
Learning Objectives
Upon completion of this activity, learners will be able to:
- Describe the benefits of earlier treatment intensification and weight loss in achieving glycemic goals and reducing the risk of CVD in patients with T2D
- Describe the latest research on the role of GLP-1 RAs and dual GIP/GLP-1 RAs in treating hyperglycemia and long-term complications of T2D
- Incorporate strategies to improve earlier risk recognition, screening, and diagnosis of microvascular and macrovascular complications in patients with T2D
- Develop complication-centric treatment plans considerate of patient preferences and individualized therapeutic targets for at-risk T2D patients
Target Audience
This activity is intended for endocrinologists, endocrinology NPs/PAs, and other members of the multidisciplinary care team.
Additional credit info
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credit(s)™ through their reciprocity agreements.